⌕
Inhibrx Biosciences · INBX · Nasdaq
Tenet 45 · Mixed
Compare
$74.18−4.48%At closeTenet 45 · Mixed
$74.18−3.48 (−4.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Inhibrx Biosciences (INBX) Stock

Inhibrx Biosciences (INBX) closed at $74.18 on Nov 17, 2026; its Tenet Score is 45 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

39 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$74.18
Nov 17, 2026
Market cap
$1.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
57.30 – 155.29
low → high · as of close, Nov 16, 2026
Tenet Score
45/100
Mixed · 340 Healthcare peers

Industry: Biological Products, Except Diagnostic Substances

Inhibrx Biosciences Inc. scores 45/100. Mixed. Strongest on financial health, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 45 is built from 2 of 4 pillars, from 25% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
45/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
10
Health
79
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Growth omitted — no data yet.
Value—QualityFHealthBGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
573.5×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
7.58
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Inhibrx Biosciences Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate target…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 59 US ETFs · top wrappers by weightSee all ETFs holding INBX →

Similar-sized companies in Biological Products, Except Diagnostic Substances

The 1 company in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
Cg Oncology Inc.CGON52$7.5B

What sector and industry is Inhibrx Biosciences in?

Inhibrx Biosciences is in the Healthcare sector and the Biological Products, Except Diagnostic Substances industry.

What is Inhibrx Biosciences' Tenet Score?

Inhibrx Biosciences' Tenet Score is 45 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.